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Abstract
Motivation: Network-based analyses of high-throughput genomics data provide a holistic, systems-level
understanding of various biological mechanisms for a common population. However, when estimating
multiple networks across heterogeneous sub-populations, varying sample sizes pose a challenge in the
estimation and inference, as network differencesmay be driven by differences in power. We are particularly
interested in addressing this challenge in the context of proteomic networks for related cancers, as the
number of subjects available for rare cancer (sub-)types is often limited.
Results: We develop NExUS (Network Estimation across Unequal Sample sizes), a Bayesian method
that enables joint learning of multiple networks while avoiding artefactual relationship between sample
size and network sparsity. We demonstrate through simulations that NExUS outperforms existing network
estimation methods in this context, and apply it to learn network similarity and shared pathway activity for
groups of cancers with related origins represented in The Cancer Genome Atlas (TCGA) proteomic data.
Availability and implementation: The NExUS source code is freely available for download at
https://github.com/pdas/NExUS.
Contact: cbpeterson@mdanderson.org
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
The last decade has seen a proliferation of large, complex datasets that
quantify molecular variables such as gene, protein, microbiome, and
population-wide genetic variation. The Cancer Genome Atlas (TCGA) is
a prime example of recent large-scale consortium-level efforts, which has
generated multi-platform ’omics measurements from>10K patients across
32 common and rare cancer types. This allows for systematic investiga-
tions into the molecular mechanisms behind various oncogenic processes.
Multiple studies have established that cancer initiation and progression
are not outcomes of a single mutation within a gene or protein, but rather
the result of a perturbation to co-ordinated networks and pathways that
correspond to basic oncogenic processes such as cell proliferation and
apoptosis (Hanahan and Weinberg, 2000; Wang et al., 2015). Therefore,
it is important to understand and characterize the underlying network de-
pendency structures within and across cancers (Cho et al., 2016; Hristov
and Singh, 2017). From a discovery standpoint, this is not only crucial to
identify new cancer biomarkers and mechanisms, but also to distinguish
the key molecular regulators of networks in different cancers (Sonabend
et al., 2014; Carro et al., 2010).
Most existing studies focus on identifying the characteristics of molec-
ular networks in individual cancer populations one at a time to understand
tumor-specific molecular interactions (Gill et al., 2014; Creixell et al.,
2015). On the other hand, researchers are beginning to recognize the
critical importance of simultaneous analysis of similar tumor types (e.g.,
in terms of cell origin, organ location, biological evolution) to under-
stand fundamental commonalities and differences (Weinstein et al., 2013;
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Tamborero et al., 2013). This has led tomultiple pan-cancer studies that en-
compass the examination of various genomic and immunologic features in
related cancers such as different squamous carcinomas (Campbell et al.,
2018), gynecologic and breast cancers (Berger et al., 2018), gastroin-
testinal adenocarcinomas (Liu et al., 2018) and urologic cancers (Chen
et al., 2017). In this article, we propose a network modeling approach for
simultaneous analysis of genomic data from related tumor types.
Probabilistic graphical models (Lauritzen, 1996) are well-established
statistical tools to conduct estimation and inference of network structures.
In particular, Gaussian graphical models (Whittaker, 1990) have gained
immense popularity because of their ability to capture global dependency
structures. In high-dimensional settings, such as genomics, sparse graph-
ical models are widely used to identify important nodes and interactions
in a network consisting of a large number of genes/proteins. Various ap-
proaches for Gaussian graphical model estimation (Yuan and Lin, 2007;
Friedman et al., 2008;Wang, 2012, 2015;Baladandayuthapani et al., 2014)
have been proposed over the years. These methods recently have been
generalized to link network estimation across multiple populations using
penalization-based (Danaher et al., 2014) or Bayesian approaches (Pe-
terson et al., 2015). The former approach is not optimal for groups with
differing levels of similarity, while the latter has scaling limitations to the
prior specification. Scalability in higher dimensions also is an issue for
other existing methods for joint estimation of sparse graphs (Guo et al.,
2011; Chun et al., 2015). Along with learning the sparse network for each
cancer type while borrowing strength across groups, another objective of
our proposed method is to avoid artefactual differences in network spar-
sity due to differing sample sizes. In an application to pan-cancer network
analysis, Kling et al. (2015) proposed an algorithmic method for joint net-
work estimation with a group-specific penalty correction based on sample
size. Their method, however, lacks a formal statistical justification of the
sample-size penalty term and its effect on the sparsity of the estimated
networks.
In this article, we propose a Bayesian approach for simultaneous
Network Estimation across Unequal Sample sizes (NExUS). The main
advantages of the NExUS method over existing methods include (i) ex-
plicit incorporation of sample size correction in network estimation which
not only allows control of the sparsity but also improves borrowing of
strength between cancer-specific networks to enable a balancing of statis-
tical power across groups; (ii) the ability to quantify a network similarity
index (NSI) which can be used as a global measure of network similar-
ity among different cancer-specific networks; (iii) automatic selection of
penalty parameters within a fully Bayesian framework, avoiding the need
for the cross-validation step required by most frequentist graphical mod-
eling approaches; and (iv) an efficient strategy for updating the precision
matrices, making the method more scalable both in terms of the number
of variables and the number of groups than existing Bayesian methods
(Peterson et al., 2015; Kundu et al., 2018).
Our methods are motivated by and applied to The Cancer Proteomic
Atlas (TCPA, Li et al., 2013) that has collected high-quality Reverse Phase
Protein Array (RPPA) data across 32 cancer types. Many of these cancers
can be divided into groups based on their histological origin, location, or
similarity of biological and oncogenic processes. In this paper, we con-
sider 4 different group of cancers, namely pan-gynecological, pan-kidney,
pan-squamous, and pan-gastrointestinal. The simultaneous analysis of the
proteomic networks of related cancers can help in robustly identifying the
common network features. In addition, it can improve power for the dis-
covery of features for rare cancers, which are sharedwith other cancers. We
analyze the shared network structure of these cancers and identify shared
pathway activity between all pairs of protein networks within the same
group of cancers. We are able to establish both global trends in network
similarity (e.g., we find that uterine carcinoma, a rare cancer, is more simi-
lar to cervical squamous cell carcinoma and endocervical adenocarcinoma,
than to other gynecological cancers), as well as pathway-specific activity
sharing (e.g., we find that the hormone receptor pathway has common
activity across the pan-gynecological group, while the RAS/MAPK and
RTK pathways have shared activation across the various types of kidney
cancers).
2 The NExUS method
Data structure and notation LetXc represent the nc × p matrix of ob-
served protein or gene expression for the cth cancer type of interest, where
c = 1, 2, . . . , C. We assume that the same set of p proteins are observed
for all subjects, but allow the sample sizes nc for each cancer type to differ.
We assume that the data for each subject i follows a multivariate normal
distribution
xc,i ∼ Np(0,Θ
−1
c ), i = 1, . . . , nc,
with mean vector 0 ∈ Rp and cancer-specific precision matrix Θc. The
multivariate normal distribution is parametrized using the precision ma-
trix Θc (rather than the covariance matrix Σc = Θ
−1
c ) since there is a
direct correspondence between the precision matrix and the conditional
independence graph among variables. Specifically, in a Gaussian graphi-
cal model, entry θcij in the precision matrixΘc is exactly 0 if and only if
the corresponding proteins i and j are conditionally independent for that
cancer type i.e. they are not connected by an edge within the conditional
dependence network (Dempster, 1972). Our statistical objectives are to
learn a sparse network for each cancer type with an approach that both
allows for borrowing of information across cancers, and avoids artefac-
tual differences in network sparsity due to differing sample sizes. We now
describe the prior formulation that allows us to achieve these goals.
2.1 Hierarchical shrinkage priors for borrowing strength
We construct a joint prior that both encourages sparsity of the precision
matrices within each cancer type and similarity across the cancer types.
To formulate this prior, we first divide the elements of each matrix into
diagonal (D) and non-diagonal (ND) elements. Let θcij denote the (i, j)
th
element of the precision matrix Θc. Since Θc is symmetric, the unique
elements of {Θc}Cc=1 can be partitioned into Cp diagonal elements and
Cp(p− 1)/2 non-diagonal elements as follows:
θD = (θ
1
11, . . . , θ
1
pp, . . . , θ
C
11, . . . , θ
C
pp)Cp×1
θND = (θ
1
12, . . . , θ
C
12, . . . , θ
1
(p−1)p, . . . , θ
C
(p−1)p)Cp(p−1)
2
×1
We put independent exponential priors with mean γ−1 on the diagonal
elements (i.e., on each element of θD), and a gamma hyperprior on the
parameter γ, with shape parameter αγ and rate parameter βγ .
To enable borrowing of strength while estimating sparse versions of
the precision matrices for the set of cancers of interest, we introduce the
shrinkage parameters λ1 and λ2, where λ1 controls the shrinkage within
each cancer type and λ2 induces similarity across the cancer types. Instead
of taking the same λ1 for each cancer type and the same λ2 for each
pair of cancers, we consider a more flexible scenario where the within-
cancer and cross-cancer shrinkage parameters are dependent on cancer
type. Let λc1 denote the individual shrinkage parameter for cancer type c,
1 ≤ c ≤ C, and λcc
′
2 denote the cross-penalty across cancer types c and
c′, 1 ≤ c < c′ ≤ C. Following Kyung et al. (2010), the conditional prior
of θND is given by (1). Here the first term aims to achieve sparsity within
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each cancer and the second term to achieve similarity across cancers.
pi(θND |σ
2) ∝ exp
(
−
1
σ
C∑
c=1
λc1
∑
i<j
|θcij |−
1
σ
∑
c<c′
λcc
′
2
∑
i<j
|θcij − θ
c′
ij |
)
(1)
Network similarity index: Taking a closer look into the role of the cross-
group penalty parameter in the model, it is evident that higher values of
(λcc
′
2 )
2 encouragemore similarity between the networks of cancer c and c′
i.e., the higher the value of (λcc
′
2 )
2 the closer the network structure (edges)
will be between two cancers (we will illustrate this in our simulations
and real data analyses). Therefore within a group of related cancers, the
similarity between cancer types c and c′ can be estimated by the penalty
(λcc
′
2 )
2, which we term the NSI.Within each group of related cancers, we
transform theNSI values of all pairs of cancers to bewithin the unit interval
using a linear monotonic mapping such that the pair of cancers with the
lowest and the highest NSI values are mapped to 0 and 1 respectively. We
term these transformed NSI values as normalized network similarity index
(NNSI).
2.2 Incorporating sample size adjustment in the priors
When estimating networks for multiple cancer types using existing meth-
ods, network sparsity will vary depending upon sample size, with larger
sample sizes generally resulting in denser graphs (more edges). From a
pan-cancer context, however, sparsity should not be dependent on the
sample size – since large cancers will overwhelm under-sampled or rare
cancers. To counteract this dependency, we design priors using shrinkage
parameters to mitigate the sample size effect. Since larger values of λc1
encourage more shrinkage of the elements of the precision matrix, and
hence more sparsity, our objective is to have a larger prior mean of (λc1)
2
for the cancer types with larger sample sizes, and a smaller prior mean
for rare cancer types with smaller sample sizes. Similarly, the shrinkage
parameters λcc
′
2 encourage similarity between cancer types c and c
′.
To achieve these goals, we put gamma priors on the squared terms
(λc1)
2 with shape parameter α1 and rate parameter βc1, for 1 ≤ c ≤ C,
and gamma priors on (λcc
′
2 )
2 with shape parameter α2 and rate parameter
βcc
′
2 , for 1 ≤ c < c
′ ≤ C. Following Kling et al. (2015), we define βc1
and βcc
′
2 as follows:
βc1 =
β1
(nec)
2
, βcc
′
2 = β2
{
nec + n
e
c′
2necn
e
c′
}2
,
where β1, β2 > 0. Let n¯ represent the average sample size across the
C cancer types. We define the effective sample size of the cth cancer
type as nec = n¯
δn
(1−δ)
c , where 0 < δ < 1. Hence, we get the prior
mean of (λc1)
2 to be
(α1
β1
)
(nec)
2, and the prior mean of (λcc
′
2 )
2 to be(α2
β2
){ 2necnec′
nec+n
e
c′
}2
. At δ = 0, nec = nc, so the prior mean depends only
on the sample size for cancer type c, while at δ = 1, nec = n¯, so the prior
mean is equal across all cancer types. As δ approaches 0, relatively more
sample size correction is induced by the prior.
An illustrative example: Consider three cancer types A, B, and C with
sample sizes nA = 50, nB = 100, and nC = 200. Then for δ < 1,
our objective is to have prior mean of (λA1 )
2 to be the smallest and the
prior mean of (λC1 )
2 to be the largest, while prior mean of (λB1 )
2 should
be in between those values. Also, for δ < 1, for similarity shrinkage
parameters, our objective is to have the lowest prior mean among the two
cancers with the smallest sample sizes (here A and B) and the highest
prior mean among the two cancers with the highest sample sizes (here B
and C). The variation of the prior means of the shrinkage parameters for
this scenario is plotted as a function of δ in Figure 1. Note that under the
proposed way of prior construction, the desired order between the prior
means of the shrinkage parameters are maintained for δ < 1. Also note
that as δ increases to 1, the penalty terms converge in both scenarios.
2.3 MCMC and edge selection
After introducing latent variables T2 andΩ2, with an appropriate choice
of prior, it can be shown that the conditional prior of equation (1) can be
re-expressed as the normal distribution
ΘND |σ
2,T2,Ω2 ∼ NCp(p−1)/2
(
0, σ2ΣΘND
)
,
where ΣΘND can be formulated in terms of T
2 and Ω2 (see supple-
mentary material Section S1). This property is important as it allows us to
construct a computationally efficient Gibbs sampler.
Since the posterior distribution is not tractable, we rely on Markov
Chain Monte Carlo (MCMC) sampling to obtain a sample from the pos-
terior distribution. Specifically, we are able to construct a Gibbs sampler
using the posterior conditional distributions for each parameter or set of
parameters. Here is a high-level outline of the updates that take place in
each iteration of the algorithm. For additional details on the joint posterior,
posterior full conditional distributions, and sampling steps, see Sections
S2–S4 in the supplementary material.
• Update the ith column ofΘc following the approach in Wang (2012)
by sampling a scalar from a gamma distribution and a vector from a
multivariate normal, and then applying an appropriate transformation
for c = 1, . . . , C and i = 1,…, p.
• Update the latent variable T2 by sampling the element (τcij )
−2 from
an inverse-gamma distribution for c = 1, . . . , C and 1 ≤ i < j ≤ p.
• Update the latent variableΩ2 by sampling the element (ωcc
′
ij )
−2 from
an inverse-gamma distribution for 1 ≤ c < c′ ≤ C and 1 ≤ i < j ≤
p.
• Update (λc1)
2 by sampling from a gamma distribution for c =
1, . . . , C.
• Update (λcc
′
2 )
2 by sampling from a gamma distribution for 1 ≤ c <
c′ ≤ C.
• Update γ by sampling from a gamma distribution.
Since the shrinkage prior results in sampled values for the precision ma-
trices that have entries, which are very close to 0, but not exactly 0,
thresholding is required to represent the sampled precision matrices as
sparse. Therefore, to identify selected edges in the estimated networks,
we choose a cut-off κ = 0.05 on the elements of the partial correla-
tion matrices (derived from corresponding precision matrices). Instead of
simply thresholding the elements of the posterior mean partial correlation
matrices, we consider a slightly different probabilistic approach. From
the posterior sample, we specifically calculate the posterior probability of
each non-diagonal entry of the partial correlation matrices being greater
than the cut-off κ. The edges corresponding to the entries with posterior
probability of inclusion greater than 0.5 across all MCMC iterations are
then selected (see supplementary material Section S5 for additional details
on the edge selection procedure).
3 Simulation studies
In this section, we compare the performance of the proposed method to
several existing methods on a simulated data set. To construct the simu-
lated data, we consider a version of the set-up on p = 20 variables and
C = 4 groups from section 5.1 of Peterson et al. (2015), modified so that
all of the graphs have at least some shared structure and there are unequal
sample sizes across groups. Specifically, the first precision matrix Θ1 is
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Figure 1: Prior means of within-cancer (λ21) and cross-cancer (λ
2
2) shrinkage parameters as a function of δ. The (a) within-cancer and (b) cross-cancer
shrinkage parameters have been shown for a scenario with 3 cancer types A, B, C with sample sizes nA = 50, nB = 100, nC = 200.
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constructed so that all its diagonal entries are 1, θi,i+1 = θi+1,i = 0.5
for i = 1, . . . , 19, θi,i+2 = θi+2,i = 0.4 for i = 1, . . . , 18, and
all remaining entries are set to 0. To construct Θ2, 5 non-zero entries
are randomly replaced by 0 out of the 37 non-zero entries of Θ1, and
5 null elements of Θ1 are replaced by values sampled uniformly from
{[−0.6,−0.4]∪ [0.4, 0.6]}. To constructΘ3, 10 edges among the shared
edges ofΘ1 andΘ2 are removed, and 10 new edges which are not present
in either of those two matrices are added in the same manner. To construct
Θ4, 5 edges among the 22 common edges of Θ1, Θ2, and Θ3 are re-
moved, and 5 new edges are added that were not present in any of the first
three matrices. To make sure the derived precision matrices are positive
definite, wedivideeachoff-diagonal element by the sumof the off-diagonal
elements in its row, and then average the matrix with its transpose (similar
to the approach taken in Danaher et al., 2014). The pairwise proportions
of edges shared across the 4 precision matrices varies from 0.46 to 0.86.
The sample sizes are taken to be (n1, n2, n3, n4) = (20, 40, 60, 80).
For each cancer type c = 1, . . . , 4, we then generate nc observations by
sampling from the multivariate normal distribution with mean zero and
precision matrix Ωc.
For the methods comparison, we consider a variety of Bayesian and
frequentist methods. In the Bayesian framework, in addition to the pro-
posed NExUS method, we consider the Bayesian graphical lasso (BGL)
and Bayesian adaptive graphical lasso (BayesAdapGL, Wang, 2012). The
values of the tuning parameters for the BGL and BayesAdapGL are the
same as those considered inWang (2012). For edge selection, however, we
use the same thresholding approach as NExUS. For NExUS, we use the
following hyperparameter setting: α1 = 1, α2 = .1, β1 = .1n¯2, β2 =
1n¯2, αγ = 1, and βγ = 1. For all three Bayesian approaches, we discard
the first 5,000 iterations as burn-in, and use the following 15,000 iterations
as the basis for inference.
In the frequentist framework, we consider both single graph and joint
estimation methods. Specifically, the single graph methods we compare to
are the graphical lasso (FreqGL) (Friedman et al., 2008), adaptive graphi-
cal lasso (FreqAdapGL), and the SCAD penalized lasso (Fan et al., 2009).
The joint estimation methods we consider are the group graphical lasso
(GGL) and fused graphical lasso (FGL) (Danaher et al., 2014). Please see
Section S6 of the supplementary material for further details regarding the
application of these methods.
Table 1. Mean AUC values of graph structure learning across 100 simulated
data sets, with standard deviations in parentheses. The results for the top two
performing methods for each cancer type are highlighted in bold.
Methods C1 C2 C3 C4
NExUS 0.83(0.03) 0.88(0.02) 0.94(0.02) 0.94(0.02)
FGL 0.85(0.02) 0.88(0.02) 0.85(0.03) 0.79(0.03)
GGL 0.80(0.03) 0.83(0.03) 0.90(0.03) 0.91(0.02)
BGL 0.84(0.05) 0.80(0.03) 0.90(0.03) 0.92(0.03)
BayesAdapGL 0.82(0.01) 0.81(0.01) 0.89(0.01) 0.92(0.00)
FreqGL 0.79(0.03) 0.77(0.04) 0.87(0.03) 0.88(0.04)
FreqAdapGL 0.68(0.06) 0.73(0.04) 0.84(0.03) 0.88(0.04)
SCAD 0.54(0.04) 0.72(0.04) 0.84(0.03) 0.89(0.04)
To compare the performance of these methods, we primarily rely on
the area under the ROC curve (AUC), as it provides a single summary of
network learning accuracy. In Table 1, we summarize the AUC values for
the various methods for each of the four simulated graph structures. The
reported value is the mean of AUC values estimated from 100 simulated
datasets. The standard error values are reported inside parentheses. In these
results, NExUS is consistently one of the top two performing methods.
FGL also performs well for groups C1 and C2, which have relatively
smaller sample sizes and benefit most from the enforcement of similarity
across graphs, but its performance is relatively worse forC3 andC4. Some
of the single graphmethods (BGLandBayesAdapGL) becomecompetitive
when applied to the group with the largest sample size, but lack power in
the classes with smaller sample sizes. In Table 2, we show the accuracy
of learning shared edges, as summarized by the AUC for each pair of
cancer types based on100 simulated datasets. Again, NExUSdemonstrates
the best overall performance, with FGL and GGL also competitive. FGL
and GGL, while achieving good performance overall, are somewhat less
flexible than NExUS, as they rely a single value for λ1 for each class and
a single value of λ2 for each pair of classes. The procedure of finding the
optimal values of those penalty parameters is computationally challenging
and not scalable for networks with a large number of nodes.
To gain insight into how NExUS improves on separate Bayesian infer-
ence, we plot the true positive rate (TPR), false positive rate (FPR), and
Mathew’s Correlation Coefficient (MCC) across a range of values for the
threshold κ on the partial correlation matrix elements in the supplemen-
tary material Figure S1. This figure demonstrates that the NExUS method
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Table 2. Mean AUC values of shared edge learning across 100 simulated data
sets, with standard errors in parentheses. The results for the top two performing
methods for each cancer type are highlighted in bold.
Methods (C1, C2) (C1, C3) (C1, C4) (C2, C3) (C2, C4) (C3, C4)
NExUS 0.83(0.02) 0.91(0.02) 0.90(0.02) 0.92(0.02) 0.92(0.02) 0.94(0.01)
FGL 0.89(0.02) 0.94(0.02) 0.85(0.02) 0.93(0.02) 0.93(0.02) 0.84(0.03)
GGL 0.81(0.03) 0.86(0.02) 0.86(0.03) 0.87(0.03) 0.88(0.03) 0.91(0.02)
BGL 0.80(0.04) 0.84(0.04) 0.83(0.04) 0.83(0.03) 0.82(0.03) 0.89(0.02)
BayesAdapGL 0.79(0.00) 0.80(0.00) 0.79(0.00) 0.82(0.00) 0.81(0.00) 0.89(0.00)
FreqGL 0.79(0.03) 0.81(0.03) 0.81(0.03) 0.77(0.05) 0.77(0.06) 0.86(0.03)
FreqAdapGL 0.68(0.06) 0.70(0.07) 0.7(0.08) 0.72(0.05) 0.71(0.05) 0.84(0.04)
SCAD 0.54(0.04) 0.54(0.05) 0.54(0.07) 0.71(0.06) 0.70(0.06) 0.85(0.04)
outperforms the Bayesian graphical lasso (BGL) across a range ofκ values
corresponding to desirable values of the TPR and FPR, primarily due to a
much faster drop-off in the FPR as κ increases. Additional details on the
simulation set-up and results (including ROC curves, MCC values, and
sensitivity analysis) are provided in supplementary material Section S6.
4 NExUS analyses of pan-cancer proteomic data
We demonstrate the utility of NExUS to conduct pan-cancer analyses of
proteomics data collected across various cancer types. We focus on the
four sub-groups of related cancers: pan-gynecological (pan-gynae), pan-
kidney, pan-squamous, and pan-gastrointestinal (pan-GI). Gynecologic
cancers have similar embryonic origins, since female hormones influence
their development (Berger et al., 2018). The pan-gynae group consists
of breast invasive carcinoma (BRCA), cervical squamous cell carcinoma
and endocervical adenocarcinoma (CESC), ovarian serous cystadenocar-
cinoma (OV), uterine corpus endometrial carcinoma (UCEC), and uterine
carcinosarcoma (UCS). Since kidney cancers originate from the cells of
the outer layer of the kidney (the renal cortex), we consider the following
cancers in the pan-kidney group: kidney chromophobe (KICH), kidney
renal clear cell carcinoma (KIRC), and kidney renal papillary cell carci-
noma (KIRP). Squamous cell carcinomas (SCCs) arise from the epithelia
of the aerodigestive and genitourinary tracts and share some histological
characteristics that can be used for predicting the site of origin, clinical
behavior, cause, prognosis, or optimal therapies (Campbell et al., 2018).
In the pan-squamous group, we consider esophageal squamous-carcinoma
(ESCA(sq)), head and neck squamous cell carcinoma (HNSC), and lung
squamous cell carcinoma (LUSC). Adenocarcinomas of the GI tract share
similar endodermal developmental origins alongwith exposure to common
insults that promote the tumor formation (Liu et al., 2018); hence the pan-
GI group consists of colon/rectum adenocarcinoma (CORE), esophageal
adeno-carcinoma (ESCA(ad)), and stomach adenocarcinoma (STAD).
Our proteomics data arises from The Cancer Proteome Atlas (TCPA,
Li et al., 2013), which provides protein abundance data for TCGA sam-
ples, and consists of RPPA-based quantifications using antibodies that
cover functions including proliferation, DNA damage, polarity, vesicle
function, EMT, invasiveness, hormone signaling, apoptosis, metabolism,
immunological and stromal function, as well as other critical cellular sig-
naling pathways (Akbani et al., 2014). The proteins profiled allow for
a focused exploration of the various functional mechanisms underlying
oncogenic processes across tumor types.
A challenge in analyzing this data is that sample sizes for different
cancers vary considerably, from 48 for UCS, to 879 for BRCA (see sup-
plementarymaterials Table S4 for the number of samples available for each
cancer type). Instead of estimating the proteomic networks for each cancer
separately, joint estimation and borrowing of strength across the networks
gives us a broader picture of the similarities and dissimilarities among the
cancers belonging to the same group. Specifically, the cross-group penalty
terms in NExUS help in identifying some of the weak signals (edges)
for the cancer networks with smaller sample sizes when those edges are
shared by other cancers of the same group, and the sample size adjustment
encourages networks with more similar levels of sparsity across cancers
belonging to the same pan-cancer group. In addition to learning the net-
work structures per cancer type, we also are able to estimate the global
proteomic network-based similarities and the pathway-specific similarities
among the cancers belonging to the same group.
For the analysis, we use the same values of the prior parameters as in
the simulation studies. We perform 20,000 iterations, discarding the first
5,000 iterations as burn-in for each pan-cancer group. We adopt the same
posterior edge selection strategy as in the simulation studies. The posterior
selected networks for each cancer type are shown in Figures S8–S21 of
the supplementary materials. Here we focus on high-level take-aways of
these pan-cancer analyses, in particular, on the global and pathway-specific
similarity measures.
4.1 Global proteomic similarity between cancers
To understand the extent of shared network structure among the cancers be-
longing to the same group, we estimate the normalized network similarity
indexes (NNSI) for each pair of cancers. We plot the NNSI in Figure 2 for
all pan-cancer groups. In the pan-gynae group we observe 3 distinct clus-
ters among the pairs of cancers based onNNSI: CESC-UCS are the closest;
OV-UCS, CESC-OV, UCEC-UCS, CESC-UCEC, and OV-UCEC belong
to the second cluster with intermediate NNSI values; and the third cluster,
which represents the most distant pairs of cancers, contains BRCA-OV,
BRCA-UCS, BRCA-CESC and BRCA-UCEC. These results show that
the protein network for the rare cancer UCS is more similar to that of
CESC and OV cancers as compared to other gynae cancers. BRCA has
the least network similarity with other gynae cancers, suggesting BRCA
has distinctive network features. In the pan-kidney group, the KICH and
KIRP networks are the closest, while KIRC and KIRP networks are least
similar. For the pan-squamous and pan-GI groups, ESCA(sq)-LUSC and
ESCA(ad)-STAD are most similar while HNSC-LUSC and CORE-STAD
are the least similar. To provide further insight into the meaning of the
network similarity index, we examined the relationship between it and the
L1 distance between pairs of precision matrices, and found the relation to
be approximately linear, where pairs of cancer with relatively high values
of the network similarity index have relatively lowerL1 distances between
them (see supplementary material Figure S5).
Finally, to visualize the extent of shared structure across each group of
cancers, we construct heatmaps of the posterior edge inclusion probabil-
ities (Figure 3). The ordering of the cancer types, which was determined
by hierarchical clustering of the edge probabilities, supports the NNSI
results, with pairs of cancer scoring higher on the NNSI grouped more
closely within the estimated hierarchy.
4.2 Pathway-specific similarity between cancers
To understand important aspects of the network similarity between can-
cer types, we conducted a deeper investigation of the proteomic networks
using available pathway information. We focus our exploration on 12well-
established curated pathways with translational relevance (Akbani et al.,
2014; Ha et al., 2018): apoptosis, cell cycle, DNAdamage response, EMT,
hormone receptor, hormone signaling breast, PI3K/AKT, RAS/MAPK,
RTK, TSC/mTOR, breast reactive, and core reactive. A few of the proteins
profiled are shared by more than one pathway (see supplementary material
Table S5). One of our main motivations for deconvolving proteomic activ-
ity into pathways is to investigate which pathways are activated in each of
the cancer types, and thereby gain a better understanding of themechanistic
and regulatory sharing of information between proteomic pathways.
To quantify pathway-specific activation, we estimate the proportion of
shared edges within each pathway and across each pair of pathways for
all cancers belonging to the same group. The heatmap for the proportion
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Figure 2: Scatter plot of normalized network similarity index (NNSI) for each pair of cancers in the (a) pan-gynae, (b) pan-kidney, (c) pan-squamous, and
(d) pan-GI groups.
0 0.2 0.4 0.6 0.8 1
 normalized network similarity index
0
0.2
0.4
0.6
0.8
1
 
n
o
rm
al
iz
ed
 n
et
w
or
k 
si
m
ila
rit
y 
in
de
x
BRCA-UCEC
BRCA-CESC
BRCA-UCS
BRCA-OV
OV-UCEC
CESC-UCEC UCEC-UCS
CESC-OV
OV-UCS
CESC-UCS
(a) pan-gynae
0 0.2 0.4 0.6 0.8 1
 normalized network similarity index
0
0.2
0.4
0.6
0.8
1
 
n
o
rm
al
iz
ed
 n
et
w
or
k 
si
m
ila
rit
y 
in
de
x
KIRC-KIRP
KICH-KIRC
KICH-KIRP
(b) pan-kidney
0 0.2 0.4 0.6 0.8 1
 normalized network similarity index
0
0.2
0.4
0.6
0.8
1
 
n
o
rm
al
iz
ed
 n
et
w
or
k 
si
m
ila
rit
y 
in
de
x
HNSC-LUSC
ESCA-HNSC
ESCA-LUSC
(c) pan-squamous
0 0.2 0.4 0.6 0.8 1
 normalized network similarity index
0
0.2
0.4
0.6
0.8
1
 
n
o
rm
al
iz
ed
 n
et
w
or
k 
si
m
ila
rit
y 
in
de
x
CORE-STAD
CORE-ESCA
ESCA-STAD
(d) pan-GI
Figure 3: Heatmap of posterior edge probabilities for each cancer in the
(a) pan-gynae, (b) pan-kidney, (c) pan-squamous, (d) pan-GI groups. For
each cancer group, out of a possible 75 ∗ (75 − 1)/2 edges, we include
only rows for the probabilities for edges selected in at least one graph in
the group.
of shared edges within and across pathways for each pair of cancers is
given in Figures S6–S7 of the supplementary materials. In general, the
proportion of shared edges are higher within pathways than across differ-
ent pathways, which is along expected lines. This makes biological sense,
as core pathway activities are likely to be preserved across different can-
cer lineages. To identify the strongest shared pathway activity for each
pair of cancers within each group, we computed the percentage of shared
edges within each pathway for each pair of cancer types. In Figure 4, we
include edges based on the ranking of these percentages of edges shared:
specifically, we include a colored link between cancer types in the figure
for the 40% highest sharing percentages across all pathways and cancer
pairs for all cancer types, except pan-gynae. As the pan-gynae group has
a larger number of cancer types included, we focus on the top 20% there
to improve legibility.
For the pan-gynae group, the hormone receptor pathway and the core
reactive pathway are the most active shared pathways across the pairs of
cancers. The hormone receptor pathway is important for OV cancer, where
hormonal-based systemic therapies are used to treat ovarian stromal tumors
(Dacheux et al., 2013). AsUCS is a rare cancer, it is challenging to pinpoint
its active pathways and to draw network-based inference. We are able to
identify the cell cycle pathway as one of the top three actively shared
pathways between UCS and UCEC. This is clinically relevant as a cell
cycle pathway inhibitor has been identified as one of the therapeutic options
for UCS (Cherniack et al., 2017). Finally, PI3K/AKT pathway activity is
shared between the BRCA and UCEC as well as BRCA and OV cancer
types. TCGA Research Network (2012b) mentions many components of
PI3K pathway were amplified in basal-like breast cancers.
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Figure 4: Shared pathway activity: Proportion of shared edges within path-
ways across all pairs of cancers, with edges denoting top 20% (for gynae)
and 40% (for other cancer groups) of all pathways for each pair of can-
cers within each group are plotted for (a) pan-gynae, (b) pan-kidney, (c)
pan-squamous, (d) pan-GI cancer groups.
For the pan-kidney group, our analysis identifies the TSC/mTOR,
RAS/MAPK, and RTK pathways as the top 3 actively-shared pathways.
We also observe shared pathway activity for the PI3/AKT, EMT, core re-
active, cell cycle, and hormone receptor pathways. Chen et al. (2016) and
TCGA Research Network (2013) recognized the PI3K/AKT and mTOR
pathways to be active for renal cell carcinoma (RCC) and clear cell renal
cell carcinoma (ccRCC). In addition, Gibbons and Creighton (2018) found
EMT as one of the important activated pathways in kidney cancers.
For the pan-squamous group, the cell cycle, RTK, and PI3K/AKT path-
ways are activated between all pairs of cancers. Other activated pathways
are TSC/mTOR, EMT, core reactive, and hormone receptor. TCGA Re-
search Network (2015) and TCGA Research Network (2012a) described
the PI3K, RAS, and AKT pathways as major pathways influencing HNSC
and LUSC, respectively. TCGAResearch Network (2015) and TCGA Re-
searchNetwork (2012a) also reported that the cell cycle andRTKpathways
play an important role in HNSC and LUSC. Finally, for the pan-GI group,
we find the hormone receptor, RTK, EMT, and core reactive pathways as
the top 3 activated shared pathways.
5 Conclusion and Remarks
In this article, we propose NExUS, a fully Bayesian method for estimating
a group of related networks usingGaussian graphical modeling. The incor-
poration of a penalty on dissimilarity across the precision matrices in the
prior specification enables borrowing of strength across the networks. This
aspect of the model is especially helpful for identifying edges in the net-
works with smaller sample sizes. In addition, the resulting NSI helps order
the relative closeness of each pair of networks within the set analyzed. An-
other novel feature of NExUS is the inclusion of a sample size correction
which encourages similar sparsity levels across networks with different
sample sizes. Our simulation studies show that NExUS outperforms other
existing methods for individual and joint estimation of networks. NExUS
is motivated by the TCGA-based RPPA dataset, wherein we estimate the
pan-cancer proteomic networks for 4 groups of related cancers lineages.
The existence of rare cancers (e.g. UCS in pan-gynae, and ESCA(ad)
in pan-GI) makes the proposed model particularly appropriate for this
application.
We developed the NExUS model under Gaussian assumptions and ap-
plied it for datasets containing a moderate number of proteins obtained
using targeted profiling. In the future, it can be modified for skewed
data and discrete variables, potentially following the methods proposed in
Bhadra et al. (2018). The method would then be applicable to non-normal
data sets such as mutation or copy number variation. Finally, more efficient
algorithms could be developed to allow NExUS to scale to a larger number
of variables, enabling an application to data sets such as the Clinical Pro-
teomic Tumor Analysis Consortium (CPTAC), which was acquired using
untargeted proteomics, and therefore has a much higher dimensionality.
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